Two Billion COVID-19 Vaccine Doses From BioNTech Expected This Year
MONDAY, Jan. 11, 2021 -- A boost in manufacturing should enable Germany's BioNTech to produce 2 billion doses of its COVID-19 vaccine this year, the company says.
BioNTech and partner Pfizer developed the first COVID-19 vaccination to be brought to market.
With three manufacturing sites in the United States and three in Europe operating or starting up soon, BioNTech expects to about double the number of doses available for this fiscal year, according to company CEO and cofounder Ugur Sahin, the Associated Press reported. The company is also looking to widen eligibility for the vaccine -- which was 95 percent effective in trials -- to include pregnant women, children, and others.
As of Jan 10, 32.9 million doses of its vaccine had been shipped, according to BioNTech, the AP reported. The vaccine has to be stored at extremely cold temperatures, but the company said it is working on a more stable version for easier use in remote regions.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Further Support and Information on COVID-19
Read this next
Mortality, Preeclampsia Up for Women With COVID-19 Giving Birth
WEDNESDAY, Jan. 20, 2021 -- Among U.S. women hospitalized for childbirth, the rates of death and certain adverse events are increased among those diagnosed with COVID-19,...
New York City May Run Out of COVID-19 Vaccines
WEDNESDAY, Jan. 20, 2021 -- New York City's COVID-19 vaccination rate has outpaced its supply of vaccine doses, and the city could run out of doses in the next few days, Mayor...
Men More Likely to Test Positive for SARS-CoV-2, Die From COVID-19
WEDNESDAY, Jan. 20, 2021 -- Men are more likely to test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to have complications of COVID-19, according...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
